Suchergebnisse - "Guan, Shaoxing"

PubPharm (18)

11

Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL : A loading dose is recommended to improve clinical outcomes

enthalten in: Clinical and translational science | 2022

von Liu, S. | Wang, Z. | Chen, R. | +10

12

Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome

enthalten in: Frontiers in pharmacology | 2022

von Liu, S. | Wang, Z. | Chen, R. | +8

13

DNA‐Thioguanine Nucleotides as a Marker for Thiopurine Induced Late Leukopenia after Dose Optimizing by NUDT15 C415T in Chinese Patients with IBD

enthalten in: Clinical Pharmacology & Therapeutics | 2022

von Zhu, X. | Chao, K. | Yang, T. | +12

14

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL : A loading dose is recommended to improve clinical outcomes

enthalten in: Clinical and Translational Science | 2022

von Liu, S. | Wang, Z. | Chen, R. | +10

15

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer

enthalten in: Translational oncology | 2021

von Guan, S. | Chen, X. | Xin, S. | +13

16

Determination of apatinib and its three active metabolites by UPLC-MS/MS in a Phase IV clinical trial in NSCLC patients

enthalten in: Bioanalysis | 2019

von Guan, S. | Shi, W. | Zhao, Z. | +10

17

Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients

enthalten in: Journal of pharmaceutical and biomedical analysis | 2019

von Guan, S. | Chen, X. | Wang, F. | +9

18

Determination of apatinib and its three active metabolites by UPLC–MS/MS in a Phase IV clinical trial in NSCLC patients

enthalten in: Bioanalysis | 2019

von Guan, S. | Shi, W. | Zhao, Z. | +10